(S,R,S)-AHPC-C1-NH2

发表于由

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白，专注于信号通路和疾病研究领域。

(S,R,S)-AHPC-C1-NH2 

(S,R,S)-AHPC-C1-NH2 是一种 E3 连接酶配体-linker 偶联物 (E3 ligase ligand-linker conjugate)，包含基于 (S,R,S)-AHPC 的 VHL 配体和 1 个 linker，可用于合成 PROTAC。

(S,R,S)-AHPC-C1-NH2

(S,R,S)-AHPC-C1-NH2 Chemical Structure

CAS No. : 2010986-20-4

规格 是否有货
5 mg 询价
10 mg 询价
25 mg 询价
50 mg 询价
100 mg 询价

* Please select Quantity before adding items.

生物活性

(S,R,S)-AHPC-C1-NH2 is a synthesized E3 ligase ligand-linker conjugate that incorporates the (S,R,S)-AHPC based VHL ligand and a linker used in PROTAC technology[1].

IC50 & Target

VHL

 

体外研究
(In Vitro)

PROTACs contain two different ligands connected by a linker; one is a ligand for an E3 ubiquitin ligase and the other is for the target protein. PROTACs exploit the intracellular ubiquitin-proteasome system to selectively degrade target proteins[2].

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.
分子量

487.61

Formula

C24H33N5O4S
CAS 号

2010986-20-4
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.
参考文献

  • [1]. Scheepstra M, et al. Bivalent Ligands for Protein Degradation in Drug Discovery. Comput Struct Biotechnol J. 2019;17:160-176. Published 2019 Jan 25.

    [2]. Nalawansha DA, et al. PROTACs: An Emerging Therapeutic Modality in Precision Medicine. Cell Chem Biol. 2020;27(8):998-985.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务